Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Study Assessing the Safety, Immunogenicity and Dose Response of VLA15, A New Multivalent Recombinant OspA Vaccine Candidate Against Lyme Borreliosis, In Healthy Adults Aged Below 40 Years

NCT03010228 is registered in ClinicalTrials.gov with Pfizer as lead sponsor.

NCT NCT03010228
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03010228 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Study Assessing the Safety, Immunogenicity and Dose Response of VLA15, A New Multivalent Recombinant OspA Vaccine Candidate Against Lyme Borreliosis, In Healthy Adults Aged Below 40 Years
Lead sponsor
Pfizer
Phase
Phase 1
Overall status
Completed
Start date
January 31, 2017
Completion date
January 16, 2019
Enrollment
179 (actual)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

lyme borreliosis, nervous system